Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. (September 2019)

• Record Type: Journal Article
• Authors: Hojbjerg, Johanne Andersen; Ebert, Eva Boysen Fynboe; Clement, Michelle Simone; Winther-Larsen, Anne; Meldgaard, Peter; Sorensen, Boe
• Is Part Of: Lung cancer. Volume 135(2019)
• Page Start: 92
• Page End: 96
• Publication Date: 2019-09
• Subjects: EGFR epidermal growth factor receptor -- TKI tyrosine kinase inhibitor -- NSCLC non-small cell lung cancer -- miRNA microRNA -- RT reverse transcription -- qPCR quantitative polymerase chain reaction -- CV coefficient of variation -- PFS progression-free survival -- RECIST response evaluation criteria in solid tumors -- OS overall survival -- CI confidence interval; NSCLC -- EGFR mutations -- MicroRNA -- Biomarkers -- Intrinsic resistance; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2019.07.005
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Intrinsic resistance to EGFR TKI is an important clinical problem. This was a prospective observational study. Patients had NSCLC, adenocarcinoma and an activating mutation in the EGFR . Plasma levels of miRNA 30b and 30c predicted erlotinib-treatment outcome. Abstract: Objectives: MiR-30b, miR-30c, miR-221 and miR-222 are known to induce gefitinib resistance in lung cancer cell lines with activation of mutations in the epidermal growth factor receptor ( EGFR ). However, the role of these four microRNAs in tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung cancer (NSCLC) patients is unknown. Thus, the aim of this study was to investigate the predictive value of miR-30b, miR-30c, miR-221 and miR-222 in plasma from EGFR -mutated lung cancer patients receiving erlotinib. Materials and methods: The cohort consisted of 29 EGFR -mutated lung cancer patients receiving erlotinib. Plasma levels of miR-30b, miR-30c, miR-221 and miR-222 were analyzed by qPCR from blood samples collected before treatment start. Plasma concentration of each microRNA was correlated to clinical outcome. Results: Plasma concentrations of miR-30b and miR-30c could be determined in all 29 patients. Low plasma concentrations of miR-30b and miR-30c showed significant correlation with superior progression-free survival (PFS) (miR-30b: HR = 0.303 [0.123–0.747], p < 0.05; miR-30c: HR = 0.264 [0.103–0.674], p < 0.05). Low plasma concentrations of miR-30c were also significantly correlated with superior overall survival (OS) (HR = 0.30 [0.094–0.954], p < 0.041). Conclusion: High plasma concentrations of miR-30b and miR-30c predicted shorter PFS and OS. This implies that miR-30b and miR-30c could have clinical potential as biomarkers in EGFR -mutated lung cancer patients.